Search Results
Sep 11, 2026, 10:15 ET Cryovials Market worth $0.31 billion by 2031 - Exclusive Report by MarketsandMarkets™
government laboratories are increasingly conducting studies that require long-term preservation of biological materials such as cells, tissues, DNA, RNA, and blood samples. This expanding research activity is driving demand for reliable cryogenic storage solutions that maintain sample quality and integrity
More news about: MarketsandMarkets
Sep 11, 2026, 08:48 ET Korea University Study Uncovers How mRNA Vaccination May Broaden Flu Antibody Responses
fine-needle aspiration of draining axillary lymph nodes to assess germinal-center responses. Researchers combined flow cytometry, ELISpot, single-cell RNA sequencing and B-cell receptor sequencing, serum IgG proteomics, and antibody binding and neutralization assays to comprehensively profile immune responses.Dr.
More news about: Korea University College of Medicine
Sep 10, 2026, 16:10 ET TransCode Therapeutics Announces Leadership Transition
Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has
More news about: TransCode Therapeutics, Inc.
Sep 10, 2026, 09:48 ET Marine Biological Laboratory Expands Board of Trustees as It Charts Its Next Chapter as an Independent Institution
from Dartmouth College's Tuck School of Business.Rachel Meyers, Ph.D., is a scientist and entrepreneur recognized for her leadership in RNA-based therapeutics. From 2003 to 2017, she served as Senior Vice President of Research and RNAi Lead Development at Alnylam Pharmaceuticals, advancing
More news about: Marine Biological Laboratory
Sep 10, 2026, 09:00 ET NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative
More news about: NeuroSense
Sep 10, 2026, 09:00 ET Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Sep 10, 2026, 07:30 ET TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
engineered to address the critical unmet need in implant-associated biofilm infections. Its distinct mechanism of action synergistically inhibits bacterial RNA polymerase, DNA gyrase, and topoisomerase IV—a triple-targeting approach that not only confers potent activity against resistant pathogens, including
More news about: TenNor Therapeutics (Suzhou) Limited
Sep 08, 2026, 19:27 ET Stowers Institute partners with Google DeepMind and leading research institutions to help reveal the regulatory language of the human genome
impact across protein-coding and non-coding regions of the genome. Researchers can then examine which molecular processes, including gene expression, RNA splicing and protein function, are predicted to be affected.The collaborating institutions explored how the resource could support several areas
More news about: Stowers Institute for Medical Research
Sep 08, 2026, 12:52 ET Cell Stem Cell: Die tBE-vermittelte Base-Editing-Therapie erzielt bei unterschiedlichen genetischen Hintergründen eine dauerhafte klinische Remission bei Sichelzellkrankheit und β-Thalassämie
genetischen Hintergründen und schließt damit den Weg von der Laborforschung zur weltweiten klinischen Anwendung ab. Unser Team befasst sich außerdem mit RNA-Editing, Prime-Editing und mitochondrialem DNA-Editing für andere Therapiebereiche."Dr. Mou Xiaodun, Geschäftsführer von Correctseq, fügte hinzu:
More news about: CorrectSequence Therapeutics
Sep 08, 2026, 08:00 ET NanoMosaic Joins Mass General Brigham-Led Consortium Awarded ARPA-H GIVE Program to Advance On-Demand Distributed Manufacturing of Genetic Medicines
networks," said lead and principal investigator Alex Wesselhoeft, Ph.D., Director of the RNA Therapeutics Core at the Mass General Brigham Gene and Cell Therapy Institute. "FUSE brings together complementary expertise in RNA manufacturing, automation, analytics, and clinical translation to help make this vision
More news about: NanoMosaic
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
applicability across diverse genetic backgrounds, completing the translational journey from bench to global clinical application. Our team is also exploring RNA editing, prime editing, and mitochondrial DNA editing for other therapeutic areas."Dr. Mou Xiaodun, CEO of Correctseq, added: "The data demonstrate
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 20:00 ET Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
applicability across diverse genetic backgrounds, completing the translational journey from bench to global clinical application. Our team is also exploring RNA editing, prime editing, and mitochondrial DNA editing for other therapeutic areas."Dr. Mou Xiaodun, CEO of Correctseq, added: "The data demonstrate
More news about: CorrectSequence Therapeutics
Sep 07, 2026, 00:36 ET Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research
476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in the high-efficiency production of circular RNA (circRNA) – a rapidly emerging modality in next-generation RNA therapeutics.
More news about: Rznomics
Sep 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Sep 04, 2026, 02:00 ET Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
Sept. 4, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that updated Phase II data from its ongoing BW-20805 study for hereditary angioedema (HAE) was selected
More news about: Argo Biopharmaceutical Co., Ltd
Sep 03, 2026, 09:00 ET Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Sep 03, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.Headquartered in Bridgewater, New Jersey, Insmed has offices and
More news about: Insmed Incorporated
Sep 02, 2026, 12:00 ET Zoghbi, Bird Honored for Work on Epigenetics in Neurological Diseases
functional MeCP2 can be reversed in mice by oligonucleotide therapy. Based on this work, a new generation of gene replacement (TSHA-102 and NGN-401) and RNA-regulating (ION 440) drugs, are now advancing through clinical development."Together, these two scientists have forged a remarkable path from
More news about: Texas Children's Hospital
Sep 02, 2026, 09:00 ET New Johns Hopkins Study Identifies Pervasive RT-qPCR Artifact in CRISPR Knockdown Studies and How UltraMarathonRT® Solves It
Guide RNAs from RNA-targeting CRISPR systems remain bound to their target mRNA after total RNA preparations and suppress conventional reverse transcription. uMRT's strand-displacing reverse transcriptase restores accurate knockdown quantification.BRANFORD,
More news about: RNAConnect
Sep 02, 2026, 09:00 ET Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines
retrotransposon, a natural gene-insertion system discovered by the company's academic co-founders. Typewriter's two-part, all-RNA therapy comprises a payload mRNA to make the R2 protein and a second RNA containing the therapeutic gene flanked by sequences to recruit the R2 protein. Inside the cell, the two assemble
More news about: Typewriter Therapeutics, Inc.
Sep 02, 2026, 08:30 ET Bypassing the Bottlenecks: Multi-Modality Considerations for Next-Gen Cell and Gene Therapy, Upcoming Webinar Hosted by Xtalks
including key distinctions between cell therapies, such as CAR-T and hematopoietic stem cell therapies, and gene therapies, including AAV-based and RNA therapeutics. The session will highlight how specialized technologies, including flow cytometry, genomics and bioanalytical (BioA) testing, work together
More news about: Xtalks
Sep 02, 2026, 08:00 ET Atrium Therapeutics to Participate in Upcoming Investor Conferences
DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences
More news about: Atrium Therapeutics
Sep 01, 2026, 10:31 ET The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
population.Advances in PCSK9-Targeted Drug Development: Innovations across monoclonal antibodies, small molecules, oral inhibitors, and RNA-based approaches are broadening the PCSK9 therapeutic landscape. Some of the PCSK9 inhibitors drugs under development include Recaticimab (Hengrui
More news about: DelveInsight Business Research, LLP
Sep 01, 2026, 09:30 ET Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Sep 01, 2026, 09:00 ET Eclipsebio expands its RNA characterization capabilities with multi-attribute nanopore-based sequencing assay eSTRAND RNA QC™
eSTRAND RNA QC™ uses nanopore-based direct RNA sequencing to offer multi-attribute RNA characterization.Using direct RNA sequencing, eSTRAND RNA QC reads full-length RNA without requiring reverse transcription or translation.eSTRAND RNA QC simultaneously measures RNA identity,
More news about: Eclipsebio